Home Technology Pipeline Our Team Contact Us
Developing Next Generation for the treatment of Central Nervous Disorders

Stress, Mood, and Behavioral Disorders

Neuropsychiatric Symptoms in Huntingtonís Disease. Irritability, anxiety, and aggression are commonly observed in a high percentage of HD patients. These neuropsychiatric manifestations of HD are difficult to treat with existing pharmacologic and behavioral approaches and have major effects on the quality of life of HD subjects and their families.

Post-Traumatic Stress Disorder (PTSD) is the most rapidly growing psychiatric diagnosis in the United States and a major issue for military medicine. Current treatments are repurposed drugs that are minimally effective.

Intermittent Explosive Disorder severely impacts quality of life and poses substantial risk to patients. Current estimates indicate up to 6% lifetime prevalence in the US alone. There are currently no approved treatments.

Anger/Aggression/Impulse Control Disorders are common co-morbidities impacting therapeutic response in multiple indications, including TBI, ADHD PTSD, and personality disorders. There are currently no approved treatments.

Major Depression and Treatment Resistant Depression (TRD). Some 50% of patients do not respond to current drug therapies; A novel, non-monoamine mechanism of action provides differentiation and an opportunity to address TRD.

Azevan Pharmaceuticals is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. The Companyís first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of neuropsychiatric symptoms in neurodegenerative diseases and a broad range of stress-related affective disorders, including Post-traumatic Stress Disorder (PTSD), Intermittent Explosive Disorder, and Major Depression. Vasopressin receptor antagonists represent a novel mechanism of action for addressing these indications.

Azevan facts
  • SRX246, our lead clinical candidate, is ready for 12 week Phase II clinical trials based on Phase I and toxicology studies.
  • Phase I trials for SRX251, the lead back-up clinical candidate, were completed, including 5-day multiple ascending dose.
  • Clinical candidates are first-in-class, orally active small molecules that cross the blood-brain barrier.
  • Azevanís library is based on proprietary azetidinone chemistry that can be manipulated to target additional high-value GPCRs.
  • Venture-backed company founded and run by experienced chemists and neurobiologists.